Mannosylated N-aryl substituted 3-hydroxypyridine-4-ones: Synthesis, hemagglutination inhibitory properties, and molecular modeling

Chemical Biology and Drug Design

Volumn 84, Issue 4, 2014, Pages 393-401

  Car, Željka ^a   Hrenar, Tomica ^a   Petrovic Perokovic, Vesna ^a   Ribic, Rosana ^a   Seničar, Mateja ^a   Tomic, Srd Strok Signanka ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Escherichia coli; FimH lectin; hemagglutination; molecular modeling; N aryl substituted 3 hydroxypyridine 4 ones; mannopyranosides

Indexed keywords

3-HYDROXY-4-PYRIDONE; ADHESIN; ANTITHROMBOCYTIC AGENT; FIMBRIA PROTEIN; FIMH PROTEIN, E COLI; MANNOSIDE; PYRIDONE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG EFFECTS; ESCHERICHIA COLI; HEMAGGLUTINATION; METABOLISM; MOLECULAR DOCKING; PROTEIN TERTIARY STRUCTURE; QUANTUM THEORY; SYNTHESIS;

ADHESINS, ESCHERICHIA COLI; BINDING SITES; ESCHERICHIA COLI; FIMBRIAE PROTEINS; HEMAGGLUTINATION; MANNOSIDES; MOLECULAR DOCKING SIMULATION; PLATELET AGGREGATION INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PYRIDONES; QUANTUM THEORY;

EID: 84929941772     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12329     Document Type: Article

References (45)

1. Sharon N., (2006) Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim Biophys Acta; 1760: 527-537.
2. Kahane I., Ofek I., (1996) Toward anti-adhesion therapy of microbial diseases. Adv Exp Med Biol, Plenum Press, New York; 408: 1-288.
3. Zopf D., Roth S., (1996) Oligosaccharide anti-infective agents. Lancet; 347: 1017-1021.
4. Karlsson K.A., (1998) Meaning and therapeutic potential of microbial recognition of host glycoconjugates. Mol Microbiol; 29: 1-11.
5. Sharon N., Ofek I., (2000) Safe as mother's milk: carbohydrates as future anti-adhesion drugs for bacterial diseases. Glycoconj J; 17: 659-664.
6. Kelly C.G., Younson J.S., (2000) Anti-adhesive strategies in the prevention of infectious disease at mucosal surfaces. Expert Opin Investig Drugs; 9: 1711-1721.
7. Ofek I., Hasty D.L., Sharon N., (2003) Anti-adhesion therapy of bacterial diseases: prospects and problems. FEMS Immunol Med Microbiol; 38: 181-191.
8. Pieters R.J., (2007) Intervention with bacterial adhesion by multivalent carbohydrates. Med Res Rev; 6: 796-816.
9. Hartmann M., Lindhorst T.K., (2011) The bacterial lectin FimH, a target for drug discovery-carbohydrate inhibitors of type 1 fimbriae-mediated bacterial adhesion. Eur J Org Chem; 2011: 3583-3609.
10. Ronald A., (2002) The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med; 113: 14S-19S.
11. Hooton T.M., Stamm W.E., (1997) Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am; 11: 551-581.
12. Foxman B., (2002) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med; 113: 5S-13S.
13. Choudhury D., Thompson A., Stojanoff V., Langermann S., Pinkner J., Hultgren S.J., Knight S.D., (1999) X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science; 285: 1061-1066.
14. Aprikian P., Tchesnokova V., Kidd B., Yakovenko O., Yarov-Yarovoy V., Trinchina E., Vogel V., Thomas W., Sokurenko E., (2007) Interdomain interaction in the FimH adhesin of Escherichia coli regulates the affinity to mannose. J Biol Chem; 282: 23437-23446.
15. Firon N., Ashkenazi S., Mirelman D., Ofek I., Sharon N., (1987) Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect Immun; 55: 472-476.
16. Kötter S., Krallmann-Wenzel U., Ehlers S., Lindhorst T.K., (1998) Multivalent ligands for the mannose-specific lectin on type 1 fimbriae of Escherichia coli: syntheses and testing of trivalent α- d -mannoside clusters. J Chem Soc Perkin Trans; 1: 2193-2200.
17. Lindhorst T.K., Kieburg C., Krallmann-Wenzel U., (1998) Inhibition of the type 1 fimbriae-mediated adhesion of Escherichia coli to erythrocytes by multiantennary α-mannosyl clusters: the effect of multivalency. Glycoconj J; 15: 605-613.
18. Touaibia M., Roy R., (2007) Glycodendrimers as anti-adhesion drugs against type 1 fimbriated E. coli uropathogenic infections. Mini-Rev Med Chem; 7: 1270-1283.
19. Almant M., Moreau V., Kovensky J., Bouckaert J., Gouin S.G., (2011) Clustering of Escherichia coli type-1 fimbrial adhesins by using multimeric heptyl α- d -mannoside probes with a carbohydrate core. Chem Eur J; 17: 10029-10038.
20. Schierholt A., Hartmann M., Lindhorst T.K., (2011) Bi- and trivalent glycopeptide mannopyranosides as inhibitors of type 1 fimbriae-mediated bacterial adhesion: variation of valency, aglycon and scaffolding. Carbohydr Res; 346: 1519-1526.
21. Hung C.S., Bouckaert J., Hung D., Pinkner J., Widberg C., DeFusco A., Auguste C.G., Strouse R., Langermann S., Waksman G., Hultgren S., (2002) Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol Microbiol; 44: 903-915.
22. Bouckaert J., Berglund J., Schembri M., De Genst E., Cools L., Wuhrer M., Hung C.-S., et al,. (2005) Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesion. Mol Microbiol; 55: 441-455.
23. Wellens A., Garofalo C., Nguyen H., Van Gerven N., Slattegĺrd R., Hernalsteens J.P., Wyns L., Oscarson S., De Greve H., Hultgren S., Bouckaert J., (2008) Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex. PLoS One; 3: e2040.
24. Sperling O., Fuchs A., Lindhorst T.K., (2006) Evaluation of the carbohydrate recognition domain of the bacterial adhesin FimH: design, synthesis and binding properties of mannoside ligands. Org Biomol Chem; 4: 3913-3922.
25. Knight S.D., Bouckaert J., (2009) Structure, function, and assembly of type 1 fimbriae. Top Curr Chem; 288: 67-107.
26. Lindhorst T.K., Kötter S., Kubisch J., Krallmann-Wenzel U., Ehlers S., Krén V., (1998) Effect of p-substitution of aryl α- d -mannosides on inhibiting mannose-sensitive adhesion of Escherichia coli-syntheses and testing. Eur J Org Chem; 1998: 1669-1674.
27. Klein T., Abgottspon D., Wittwer M., Rabbani S., Herold J., Jiang X., Kleeb S., et al,. (2010) FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem; 53: 8627-8641.
28. Díaz M.D., del Carmen Fernández-Alonso M., Cuevas G., Cañada F.J., Jiménez-Barbero J., (2008) On the role of aromatic-sugar interactions in the molecular recognition of carbohydrates: a 3D view by using NMR. Pure Appl Chem; 80: 1827-1835.
29. Laughrey Z.R., Kiehna S.E., Riemen A.J., Waters M.L., (2008) Carbohydrate-π interactions: what are they worth? J Am Chem Soc; 130: 14625-14633.
30. Santos M.A., Marques S.M., Chaves S., (2012) Hydroxypyridinones as "privileged" chelating structures for the design of medicinal drugs. Coord Chem Rev; 256: 240-259.
31. Ma Y., Zhou T., Kong X., Hider R.C., (2012) Chelating agents for the treatment of systemic iron overload. Curr Med Chem; 19: 2816-2827.
32. Queiros C., Amorim M.J., Leite A., Ferreira M., Gameiro P., De Castro B., Biernacki K., Magalhaes A., Burgess J., Rangel M., (2011) Nickel(II) and cobalt(II) 3-hydroxy-4-pyridinone complexes: synthesis, characterization and speciation studies in aqueous solution. Eur J Inorg Chem; 2011: 131-140.
33. Green D.E., Bowen M.L., Scoot L.E., Storr T., Merkel M., Böhmerle K., Thompson K.H., Patrick B.O., Schugar H.J., Orvig C., (2010) In vitro studies of 3-hydroxy-4-pyridinones and their glycosylated derivatives as potential agents for Alzheimer's disease. Dalton Trans; 39: 1604-1615.
34. Scott L.E., Telpoukhovskaia M., Rodriguez-Rodriguez C., Merkel M., Bowen M.L., Page B.D.G., Green D.E., Storr T., Thomas F., Allen D.D., Lockman P.R., Patrick B.O., Adam M.J., Orvig C., (2011) N-aryl-substituted 3-(β- d -glucopyranosyloxy)-2-methyl-4(1H)-pyridinones as agents for Alzheimer's therapy. Chem Sci; 2: 642-648.
35. Klemm P., Jørgensen B.J., van Die I., de Ree H., Bergmans H., (1985) The fim genes responsible for synthesis of type 1 fimbriae in Escherichia coli, cloning and genetic organization. Mol Gen Genet; 199: 410-414.
36. Ribic R., Kovačevic M., Petrovic Perokovic V., Gruic-Sovulj I., Rapic V., Tomic S., (2010) Synthesis and biological activity of mannose conjugates with 1-adamantamine and ferrocene amines. Croat Chem Acta; 83: 421-431.
37. Kovačevic M., Barišic L., Ribic R., Petrovic Perokovic V., Tomic S., Rapic V., (2012) Ferrocene conjugates with mannose: synthesis and influence of ferrocene aglycon on mannose-mediated adhesion of Escherichia coli. Appl Organomet Chem; 26: 74-79.
38. Stewart J.J.P., (2007) Optimization of parameters for semiempirical methods. V. Modification of NDDO approximations and application to 70 elements. J Mol Model; 13: 1173-213.
39. Dapprich S., Komáromi I., Byun K.S., Morokuma K., Frisch M.J., (1999) A new ONIOM implementation in Gaussian 98. 1. The calculation of energies, gradients and vibrational frequencies and electric field derivatives. J Mol Struct (Theochem); 462: 1-21.
40. Frisch M.J., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., Scalmani G., et al,. (2013) Gaussian 09, Revision D.01. Wallingford, CT: Gaussian, Inc.
41. Lindhorst T.K., (2003) Essentials of Carbohydrate Chemistry and Biochemistry, 2nd edn. Weinheim: Wiley-VCH; 84 p.
42. Jakopčic K., Tamhina B., Zorko F., Herak M.J., (1977) Synthesis and physical properties of some new 4-pyridone extractants. J Inorg Nucl Chem; 39: 1201-1203.
43. Abgottspon D., Rölli G., Hosch L., Steinhuber A., Jiang X., Schwardt O., Cutting B., Smiesko M., Jenal U., Ernst B., Trampuz A., (2010) Development of an.aggregation assay to screen FimH antagonists. J Microbiol Methods; 82: 249-255.
44. Rabbani S., Jiang X., Schwardt O., Ernst B., (2010) Expression of the carbohydrate recognition domain of FimH and development of a competitive binding assay. Anal Biochem; 407: 188-195.
45. Han Z., Pinkner J.S., Ford B., Obermann R., Nolan W., Wildman S.A., Hobbs D., Ellenberger T., Cusumano C.K., Hultgren S.J., Janetka J.W., (2010) Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem; 53: 4779-4792.